Prostatype Genomics AB (ST:PROGEN) — Stock Price
Prostatype Genomics AB (ST:PROGEN) is currently trading at Skr0.10 SEK, down 30.10% today. Over the past 52 weeks, shares have ranged between Skr0.10 and Skr1.95. This page tracks Prostatype Genomics AB's live share price on the ST exchange, its daily price and volume history, and — where reported — its income statement, balance sheet, cash flow statement, and earnings history. For company valuation and market capitalisation context, see PROGEN market cap.
Prostatype Genomics AB (PROGEN) Stock Price Chart — Daily History & Trading Volume
The chart below tracks Prostatype Genomics AB's daily closing share price and trading volume on the ST exchange over the past year, giving a clear view of recent price momentum and liquidity.
Prostatype Genomics AB Income Statement — Revenue, Profit & Earnings by Year
Prostatype Genomics AB's annual income statement shows how revenue converts into profit each fiscal year, including gross profit, operating income, EBITDA, and net income.
| Fiscal Year | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Total Revenue | Skr199.00K | Skr1.36 Million | Skr683.00K | Skr10.00K | Skr683.88K |
| Cost of Revenue | Skr-1.72 Million | Skr-2.37 Million | Skr13.49 Million | Skr-2.50 Million | Skr14.89 Million |
| Gross Profit | Skr1.92 Million | Skr3.73 Million | Skr683.00K | Skr2.51 Million | Skr-14.20 Million |
| Research & Development | Skr2.21 Million | Skr3.23 Million | Skr3.51 Million | Skr1.49 Million | Skr2.41 Million |
| SG&A | — | — | Skr13.49 Million | Skr8.49 Million | — |
| Total Operating Expenses | Skr42.77 Million | Skr42.98 Million | Skr29.37 Million | Skr18.06 Million | Skr2.41 Million |
| Operating Income | Skr-40.85 Million | Skr-39.25 Million | Skr-28.69 Million | Skr-15.55 Million | Skr-16.62 Million |
| EBITDA | Skr-37.40 Million | Skr-38.02 Million | Skr-26.79 Million | Skr-15.46 Million | Skr-15.76 Million |
| EBIT | Skr-39.38 Million | Skr-39.90 Million | Skr-28.69 Million | Skr-15.55 Million | Skr-15.91 Million |
| Interest Expense | Skr1.68 Million | Skr1.54 Million | Skr397.00K | Skr81.49K | Skr1.49 Million |
| Income Before Tax | Skr-41.05 Million | Skr-41.44 Million | Skr-29.09 Million | Skr-15.63 Million | Skr-17.41 Million |
| Income Tax Expense | — | Skr1.71 Million | Skr1.68 Million | Skr-148.07K | Skr-2.00 |
| Net Income | Skr-41.05 Million | Skr-41.44 Million | Skr-29.09 Million | Skr-15.63 Million | Skr-17.41 Million |
Prostatype Genomics AB Balance Sheet — Assets, Liabilities & Shareholder Equity
The balance sheet below summarizes Prostatype Genomics AB's financial position at each fiscal year-end — what it owns (assets), what it owes (liabilities), and the resulting shareholder equity.
| Fiscal Year | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Total Assets | Skr41.97 Million | Skr49.22 Million | Skr30.95 Million | Skr40.20 Million | Skr33.66 Million |
| Total Current Assets | Skr11.82 Million | Skr25.91 Million | Skr14.17 Million | Skr21.59 Million | Skr17.46 Million |
| Cash & Equivalents | — | — | — | — | — |
| Short-term Investments | — | Skr21.49 Million | Skr6.68 Million | Skr10.50 Million | — |
| Net Receivables | Skr1.78 Million | Skr1.53 Million | Skr2.50 Million | Skr1.07 Million | Skr1.20 Million |
| Inventory | Skr95.00K | Skr203.00K | Skr44.00K | Skr107.52K | Skr394.95K |
| Property, Plant & Equipment | — | — | Skr3.60K | Skr14.09K | Skr28.22K |
| Goodwill | — | — | — | — | — |
| Total Liabilities | Skr8.50 Million | Skr24.55 Million | Skr4.80 Million | Skr4.30 Million | Skr5.37 Million |
| Total Current Liabilities | Skr8.50 Million | Skr24.48 Million | Skr4.33 Million | Skr3.43 Million | Skr4.31 Million |
| Long-term Debt | Skr0.00 | Skr67.00K | Skr466.67K | Skr866.67K | — |
| Net Debt | Skr-9.42 Million | Skr8.98 Million | Skr-3.94 Million | Skr-8.56 Million | Skr-14.40 Million |
| Total Stockholder Equity | Skr33.47 Million | Skr24.67 Million | Skr26.15 Million | Skr35.91 Million | Skr28.29 Million |
| Retained Earnings | — | Skr0.00 | Skr-141.25 Million | Skr-114.02 Million | Skr-95.89 Million |
Prostatype Genomics AB Cash Flow Statement — Operating, Investing & Financing Activities
This cash flow statement breaks down how Prostatype Genomics AB generates and spends cash across operating, investing, and financing activities each fiscal year, including free cash flow and capital expenditures.
| Fiscal Year | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Operating Cash Flow | Skr-44.71 Million | Skr-29.14 Million | Skr-27.69 Million | Skr-16.08 Million | Skr-14.71 Million |
| Capital Expenditures | Skr7.86 Million | Skr8.56 Million | Skr2.00 | Skr2.50 Million | Skr26.20K |
| Free Cash Flow | Skr-52.57 Million | Skr-37.70 Million | Skr-27.69 Million | Skr-18.58 Million | Skr-14.74 Million |
| Investing Cash Flow | Skr-8.36 Million | Skr-8.57 Million | — | Skr-2.50 Million | Skr-3.26 Million |
| Financing Cash Flow | Skr59.75 Million | Skr28.91 Million | Skr18.85 Million | Skr23.05 Million | Skr31.14 Million |
| Dividends Paid | — | — | — | — | — |
| Stock-Based Compensation | — | — | — | — | — |
| Depreciation | Skr1.98 Million | Skr1.88 Million | Skr1.90 Million | Skr88.48K | Skr149.05K |
| Change in Cash | Skr6.74 Million | Skr-8.81 Million | Skr-8.84 Million | Skr4.47 Million | Skr13.17 Million |
Prostatype Genomics AB Earnings History — EPS Actual vs. Analyst Estimates
Track Prostatype Genomics AB's quarterly earnings per share (EPS) against Wall Street estimates, along with the earnings surprise percentage for each reporting period.
| Report Date | EPS Actual | EPS Estimate | Surprise |
|---|---|---|---|
| Aug 17, 2023 | -80.00 | -100.00 | +20.00% |
| May 31, 2023 | -0.11 | — | — |
| Feb 16, 2023 | -0.36 | — | — |
| Nov 10, 2022 | -0.42 | — | — |
| Aug 18, 2022 | -0.49 | — | — |
| May 12, 2022 | -0.35 | — | — |
| Feb 24, 2022 | -0.36 | — | — |
| Sep 30, 2021 | -13.49 | — | — |